Traveler's Diarrhea Clinical Trial
Official title:
PTM202 and Modulation of Host Resistance to Diarrheagenic Escherichia Coli in a Randomized, Double-blind, Placebo Controlled Study in Healthy Human Subjects
The APA12/PANTER study is a parallel 3-weeks intervention study. Subjects will be randomly assigned to one of two treatment groups; placebo or PTM202 (n=36 per group). After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli at study day 14. At various time points before and after diarrheagenic E. coli challenge an online diary will be kept to record information on stool consistency, frequency and severity of symptoms and stool samples will be collected to determine total fecal wet weight and percentage of fecal wet weight.
The APA12/PANTER study is a randomized, double-blind, placebo-controlled, parallel
intervention study of 3 weeks in 72 healthy adults. The study will include 2 arms; PTM202 and
placebo. Subjects will be instructed to maintain their usual pattern of physical activity and
their habitual food intake, but to standardize their dietary calcium intake. After an
overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic
E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
At study day 14, 15 and 16 subjects will receive either placebo or PTM202, a dietary formula
containing dried bovine colostrum and dried whole egg.
Before and after the diarrheagenic E. coli challenge an online diary will be kept to record
information on stool consistency, frequency, severity of symptoms and mediation intake. At
various time points before and after diarrheagenic E. coli challenge stool samples will be
collected. The main study parameters are Stool consistency (Bristol Stool Scale reported by
the subjects in the online diary, and Percentage of fecal wet weight (% determined by
freeze-drying).
Secondary study parameters are: Stool frequency (Stools per day reported by the subjects in
the online diary), Total fecal wet weight (fecal weight in g/day), and the incidence and
severity of Gastro-intestinal symptoms (Gastro-intestinal Symptom Rating Scale reported by
the subjects in the online diary).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00672035 -
Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study
|
Phase 2 | |
Completed |
NCT01208922 -
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
|
Phase 3 | |
Completed |
NCT01142089 -
Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)
|
Phase 3 | |
Not yet recruiting |
NCT04026984 -
Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
|
Phase 2 | |
Not yet recruiting |
NCT04027894 -
Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
|
Phase 2 | |
Completed |
NCT03866291 -
ESBL in Patients Returning to Sweden With Traveller's Diarrhoea
|
||
Completed |
NCT01040325 -
Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study
|
Phase 2 | |
Withdrawn |
NCT02736539 -
Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea
|
Phase 3 |